Insights Into the Pathological Glycosylation Associated With COG6‐CDG

Background and Aims Congenital disorders of glycosylation (CDG) are rare diseases caused by defects in protein glycosylation. We present an infant with multisystemic clinical involvement, diagnosed with COG6‐CDG. Methods Serum and transferrin‐linked N‐glycans, as well as serum and apolipoprotein CIII–linked O‐glycans, were analyzed by MALDI mass spectrometry. Mutation analysis was performed by next‐generation sequencing. Functional studies assessed COG6 subunit expression, cooperating subunits, and retrograde transport. GlycoWorks RapiFluor‐MS–based N‐glycan labeling with HPLC‐FLD and ESI‐Orbitrap mass spectrometry enabled further comprehensive glycoprofile analysis. Results Aberrant glycosylation typical of combined N‐ and O‐glycosylation defects was detected. Mutation analysis identified a novel homozygous variant in the COG6 gene: c.906_907delinsA, p.(His302GlnfsTer4), introducing a premature stop codon and producing a truncated protein of only 304 amino acids. The diagnosis of COG6‐CDG was confirmed by the complete absence of the COG6 subunit, impairment of two other cooperating subunits, and delayed retrograde transport. Independent glycoprofile analyses by HPLC‐FLD and ESI‐Orbitrap revealed a set of potential glycobiomarkers of COG6‐CDG, including underprocessed N‐glycans Hex3‐5HexNAc2, Hex3‐5HexNAc3, Hex3‐4HexNAc4, and Hex4HexNAc3‐4NeuAc1. Conclusion This study describes a novel COG6 variant leading to complete loss of protein function and major glycosylation abnormalities. Multiomics analysis provided deeper insights into the molecular mechanisms of this rare disease and the function of the COG6 gene and demonstrated how the mutation results in significant alterations in the patient′s (glyco)phenotype.